Cannabis Is Not the Hero or the Villain. It Is a Variable.
Most cannabis coverage picks a team. On one side, a plant that cures everything and harms no one. On the other, a gateway to ruin and a generation of burnouts. Both camps can find a study, a statistic and a heartbreaking story to prove it.
I want to spend this piece on a story that does not fit either camp. Men’s Health recently looked at life with a medical marijuana card, and the person at the center of it was helped by cannabis. That is the reason I am pointing to it. Not because one story settles anything, but because we rarely let the helped person into the conversation without either canonizing them or accusing them of rationalizing.
A clear note before we go further: this is not medical advice, and I am not recommending cannabis to anyone. I am looking at one outcome and the evidence around it, objectively.
Why One Story Is Worth Telling
An anecdote is a real data point about a real person. It is not an average. If a man tells me that cannabis ended months of sleepless nights, I do not get to wave that away because a trial says otherwise, and I do not get to treat it as proof that the trial is wrong. It is information about what is possible for some people.
The opposite error is equally common. Addiction medicine sees the people for whom cannabis became a problem, and those cases are just as real. Both perspectives are honest, and both are partial.
So let us put the story next to the best controlled evidence we have.
In 2022, researchers at Massachusetts General Hospital and Harvard, led by Jodi Gilman, published a randomized clinical trial in JAMA Network Open on exactly this question: what does obtaining a medical marijuana card do for people who want it for pain, insomnia, or anxiety and depression?
The setup was pragmatic. They recruited 186 adults in the Greater Boston area between 2017 and 2020. Participants were randomized to get a card right away or to wait twelve weeks. Everyone could pick their own products, doses and frequency from a dispensary, and everyone could continue their usual medical care.
The results cut in more than one direction:
-
Sleep improved. The immediate-card group reported fewer insomnia symptoms than the waiting group.
-
Well-being improved. They also reported better mental well-being and lower perceived stress.
-
Pain, anxiety and depression did not measurably change. No significant difference showed up on those measures.
-
Cannabis use disorder rose. Among the immediate-card group, 17.1% developed it during the trial, compared with 8.6% in the waiting group, an adjusted odds ratio of 2.88. Those whose main complaint was anxiety or depression were more affected.
Notice what that is not. It is not “cannabis works.” It is not “cannabis is a trap.” It is a split verdict. And the part I find most interesting is the detail buried in the discussion: the researchers noted that people whose primary concern was insomnia were unlikely to develop cannabis use disorder, which hints that the answer depends on who you are and why you are using.
Gilman herself said in an interview that people often go to a dispensary and take advice from staff who generally have no medical training. They pick what sounds interesting and see what happens. That is a design flaw in our system, not necessarily in the plant.
The Card Is Not Just a Symptom
Here is a wrinkle that muddies the pro-cannabis story, and I would be a bad writer if I skipped it.
Research from RAND and USC followed young adults for a year. About 19% of them obtained a medical card in that time. The striking finding was that frequency of use, not physical or mental health problems, was what predicted who got one. Each additional day of use at the start raised the odds of having a card a year later by 7%. Men were nearly three times as likely as women to get one.
What does this tell us? Partly that a medical card can be a marker of heavy use rather than a marker of illness. That does not mean the person in the Men’s Health story was gaming the system. It means that when we count how many card holders report benefits, we are not looking at a random sample of sick people.
Meanwhile, getting a card keeps getting easier. Industry guides in 2026 describe telemedicine pathways that can produce one within a day in states that allow them. That is a feature for the patient who has suffered for years, and a weakness for everyone else.
So What Do We Do With a Split Verdict?
I will tell you what I do not do. I do not average it into mush and declare cannabis “complicated,” as though that were a conclusion. I try to work out which part of the split applies to a given situation.
The sleep signal is consistent with the person in the story, and the trial gives us a reasonable hypothesis: for some people with insomnia, cannabis may help, and the risk of developing a use disorder appears lower in that group. The pain signal, at least in this trial, was not there, even though many people report relief. That mismatch is worth studying, not dismissing. A twelve-week trial with self-selected products measures something specific. It does not settle what a tailored, supervised regimen can do.
Notice how this resembles other medicine. Antidepressants help many and do nothing for others. Opioids relieve acute pain and wreck lives. We tolerate nuance for pharmaceuticals because we accept that drugs have profiles. Cannabis just earned the right to the same treatment about a decade after everyone else.
If I were designing a sane personal experiment, and again I am not advising anyone, I would borrow from the trial itself. Pick a specific target symptom. Set a defined window, as the researchers did with twelve weeks. Track the symptom and the use honestly. Involve a clinician who will take the topic seriously. Ask yourself, at the end, whether you got what you were after and whether your use drifted. These are reasonable questions for any substance.
Binary Thinking Is a Habit, Not a Fact
Yes-or-no thinking is convenient, and for a long time it was how we ran drug policy. Safe or dangerous. Medicine or poison. Good people or addicts. The Controlled Substances Act is a monument to it, one big switch with five positions.
If you follow astrology, some people say we are leaving the Age of Pisces, with its either-or religious and political structure, and entering the Age of Aquarius. I cannot vouch for the calendar, and the astronomers will tell you the dates are loose. But I like the metaphor. Whether you attribute it to the stars or to a decade of better data, the instinct is the same: stop asking whether cannabis is good or evil, and start asking what it does, for whom, in what dose, with what risk.
That demands more than a slogan. Binary thinking is easy: pick a side, collect confirming facts, stop reading. Nuance means holding two uncomfortable truths at once: a card holder might be genuinely better off, and the same system can leave some users with a use disorder. The commentator who cannot tolerate both is selling something.
What This Means for the Policy Fight
If both outcomes are real, then the policy question is how to widen the first and narrow the second.
That points to better medical oversight, not less cannabis access. Dispensary staff should not be the only guidance a patient gets. Doctors need training on cannabinoids that medical schools have been slow to provide, partly because research on Schedule I substances is so hard to do. The Controlled Substances Act reform I wrote about earlier this week would help with exactly that, by making real research possible. We cannot learn who benefits if we are barred from studying it.
It also points to honesty about risk. If 17.1% of new card holders in a controlled trial developed a use disorder in twelve weeks, saying that cannabis has no addiction potential is not a defensible position. I have seen advocates make that claim, and every time they do, they hand ammunition to Dr. Siegel and his colleagues.
The person in the Men’s Health story got something good from a plant. The same plant, with a different person and a different pattern, gives other people a problem. Both are true, and neither is a footnote.
Do not be the person who needs cannabis to be a miracle, and do not be the person who needs it to be a menace. Be the person who asks what the evidence says about this particular use, for this particular purpose, and who is willing to change their mind when the data changes.
It is not as satisfying as a slogan. It is a lot more likely to be right.
Sources
- Men’s Health, article on having a medical marijuana card: https://www.menshealth.com/health/a74032480/having-a-medical-marijuana-card/
- Gilman JM, et al. “Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial.” JAMA Network Open 2022;5(3):e222106. doi:10.1001/jamanetworkopen.2022.2106. Abstract: https://www.issup.net/node/16985
- Healio coverage of the Gilman trial: https://www.healio.com/news/psychiatry/20220329/medical-marijuana-card-ownership-linked-to-cannabis-use-disorder
- HMP Global Learning Network coverage (insomnia and CUD risk; well-being): https://www.hmpgloballearningnetwork.com/site/neuro/news/access-medical-marijuana-improved-insomnia-no-change-pain-anxiety
- Mass General Psychiatry, interview with Jodi Gilman, July 2022: https://mghpsychnews.org/conversations-on-mental-health-jodi-gilman-phd-the-center-for-addiction-medicine
- Pedersen et al. (RAND/USC), “Why young adults obtain a medical marijuana card”: https://www.orthoatlanta.com/health-news/many-young-adults-misusing-medical-marijuana-study-suggests and https://pmc.ncbi.nlm.nih.gov/articles/PMC6900992
- GreenState, medical card via telemedicine in 2026: https://www.greenstate.com/explained/medical-marijuana-card-telemedicine/
MORE ON MMJ CARDS, READ THIS…
